组学
表观遗传学
精密医学
代谢组学
基因组学
蛋白质组学
疾病
计算生物学
个性化医疗
生物信息学
动脉粥样硬化性心血管疾病
计算机科学
医学
DNA甲基化
生物
基因组
内科学
病理
遗传学
基因
基因表达
作者
Liv Tybjærg Nordestgaard,Brooke N. Wolford,David de Gonzalo‐Calvo,Miron Sopić,Yvan Devaux,Ljubica Perisic Matic,Stephanie Bezzina Wettinger,Johannes A. Schmid,Núria Amigó,L. Masana,Alberico Luigi Catapano,Dimitris Kardassis,Paolo Magni
出处
期刊:Atherosclerosis
[Elsevier BV]
日期:2025-06-26
卷期号:408: 120414-120414
被引量:35
标识
DOI:10.1016/j.atherosclerosis.2025.120414
摘要
BACKGROUND AND AIMS: Atherosclerotic cardiovascular disease (ASCVD) is among the leading causes of death worldwide, and technological advances have made it possible to expand the repertoire of biomarkers used in diagnostics and treatment of ASCVD. These include different omics (genomics, epigenomics, transcriptomics, proteomics, and metabolomics). We introduce the various layers of omic data and how they can be used in diagnostics and treatment of ASCVD. Further, we discuss future possibilities of combining multiomic data with machine learning (ML) and artificial intelligence (AI) to develop algorithms for facilitating precision medicine. METHODS: we reviewed the current literature on omic data in ASCVD and its integration with ML/AI. RESULTS: Genomics has been used to generate polygenic risk scores (PRS), which have shown promising results in risk prediction of ASCVD. Key epigenetic changes implicated in atherosclerosis include deoxyribonucleic acid (DNA) methylation. Transcriptomics has been used to identify transcripts, including micro ribonucleic acid (miRNAs), implicated in atherosclerosis progression. Proteomic risk scores have shown independent predictive information and outperformed clinical risk models, and within the metabolomics field, lipidomics has emerged as a promising predictive tool. The combination of multiomic data analysis with ML and AI methods has already demonstrated potential in the development of clinical models. CONCLUSIONS: A major effort is necessary to bring omic data and technologies to the clinical field. Further support will be offered by the generation of clinically applicable/approved AI/ML algorithms able to translate large datasets into valuable information for accurate precision medicine approaches.
科研通智能强力驱动
Strongly Powered by AbleSci AI